

Supporting treatment decisions for patients with Alzheimer's disease using explainable artificial intelligence

Norway Life Science 2026, January 12, 2026




Esten H. Leonardsen

Chief Scientific Officer, baba.vision

Post-doctoral research fellow,
Department of Psychology,
University of Oslo

baba vision







New medications



New treatment options for Alzheimer's disease




Van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., ... & Iwatsubo, T. (2023). Lecanemab in early Alzheimer's disease. *New England Journal of Medicine*, 388(1), 9-21.





Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., ... & Kaul, S. (2023). Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. *JAMA*, 330(6), 512-527.





New treatment options for Alzheimer's disease





New treatment options for Alzheimer's disease





New treatment options for Alzheimer's disease





New treatment options for Alzheimer's disease



New treatment options for Alzheimer's disease



New treatment options for Alzheimer's disease



The future of Alzheimer's treatment

Thank you for your attention!
esten@baba-vision.com

baba vision

